OCPNF Quote, Financials, Valuation and Earnings

PeptiDream Inc. has a net margin of 8.15% compared to Olympus Corp.'s net margin of -25.38%. Olympus Corp.'s return on equity of 13.16% beat PeptiDream Inc.'s return on equity of -10.42%.

Olympus Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus Corp. has higher upside potential than PeptiDream Inc., analysts believe Olympus Corp. is more attractive than PeptiDream Inc..

Olympus Corp. has a beta of 0.606, which suggesting that the stock is 39.436% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.

Olympus Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.07%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus Corp. pays 19.42% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Olympus Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus Corp. quarterly revenues are $1.7B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Olympus Corp.'s net income of $136.9M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Olympus Corp.'s price-to-earnings ratio is 21.71x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus Corp. is 2.16x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma Co., Ltd. has a net margin of 8.15% compared to Olympus Corp.'s net margin of -24.76%. Olympus Corp.'s return on equity of 13.16% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.

Olympus Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus Corp. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Olympus Corp. is more attractive than Nxera Pharma Co., Ltd..

Olympus Corp. has a beta of 0.606, which suggesting that the stock is 39.436% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.

Olympus Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.07%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus Corp. pays 19.42% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Olympus Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus Corp. quarterly revenues are $1.7B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Olympus Corp.'s net income of $136.9M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Olympus Corp.'s price-to-earnings ratio is 21.71x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus Corp. is 2.16x versus 2.29x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Stemcell Holdings, Inc. has a net margin of 8.15% compared to Olympus Corp.'s net margin of --. Olympus Corp.'s return on equity of 13.16% beat Stemcell Holdings, Inc.'s return on equity of --.

Olympus Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Olympus Corp. has higher upside potential than Stemcell Holdings, Inc., analysts believe Olympus Corp. is more attractive than Stemcell Holdings, Inc..

Olympus Corp. has a beta of 0.606, which suggesting that the stock is 39.436% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Olympus Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.07%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olympus Corp. pays 19.42% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Olympus Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Olympus Corp. quarterly revenues are $1.7B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Olympus Corp.'s net income of $136.9M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Olympus Corp.'s price-to-earnings ratio is 21.71x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus Corp. is 2.16x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical Co., Ltd. has a net margin of 8.15% compared to Olympus Corp.'s net margin of -1.05%. Olympus Corp.'s return on equity of 13.16% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.

Olympus Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 14.43%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Olympus Corp., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Olympus Corp..

Olympus Corp. has a beta of 0.606, which suggesting that the stock is 39.436% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.

Olympus Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.07%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.23% to investors and pays a quarterly dividend of $0.32 per share. Olympus Corp. pays 19.42% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Olympus Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.

Olympus Corp. quarterly revenues are $1.7B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Olympus Corp.'s net income of $136.9M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Olympus Corp.'s price-to-earnings ratio is 21.71x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 198.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olympus Corp. is 2.16x versus 1.68x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.